Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering

Rhea-AI Summary

Innocan Pharma (symbol: INNPD) announced it anticipates listing on NYSE American on or around January 7, 2026, subject to listing application approval and continued compliance with exchange rules. The company said its common shares are expected to continue trading on OTCQB until the close of market on or about January 6, 2026, after which OTCQB trading will terminate upon NYSE effectiveness. Innocan will remain listed on the Canadian Securities Exchange under INNO. Concurrently, the company is conducting a securities offering subject to market conditions and regulatory approval; additional offering details will be disclosed in SEC and SEDAR+ filings.

Positive

• Anticipated NYSE American listing on ~Jan 7, 2026
• OTCQB trading to continue until close of market Jan 6, 2026
• CSE listing retained under INNO

Negative

• Concurrent offering is subject to market conditions and regulatory approval

Key Figures

Expected NYSE American listing date: January 7, 2026 OTCQB trading end date: January 6, 2026

2 metrics

Expected NYSE American listing date January 7, 2026 Anticipated effective date of NYSE American listing, subject to approval

OTCQB trading end date January 6, 2026 Common shares expected to trade on OTCQB until market close

Market Reality Check

Vol: Reported volume is 0 vers...

normal vol

Volume Reported volume is 0 versus a 20-day average volume of 336 shares. normal

Technical 200-day moving average is 11.04, with technical signal indicating trading above this level pre-news.

Market Pulse Summary

This announcement centers on Innocan’s anticipated listing on NYSE American around January 7, 2026 a...

Analysis

This announcement centers on Innocan’s anticipated listing on NYSE American around January 7, 2026 and a concurrent securities offering, subject to regulatory approvals and market conditions. Shares are expected to leave the OTCQB while remaining on the CSE under “INNO.” Investors may focus on upcoming SEC and SEDAR+ filings for offering terms, monitoring how this listing and capital-raising step interacts with existing trading history and liquidity conditions.

Key Terms

nyse american, otcqb, canadian securities exchange, sedar+, +1 more

5 terms

nyse american financial

"announced that it anticipates to list on NYSE American on or around January 7"

NYSE American is a stock exchange where companies can list their shares to be bought and sold by investors. It functions like a marketplace, helping businesses raise money and providing investors with opportunities to buy ownership in these companies. Its role is important because it facilitates the trading of smaller or emerging companies, offering investors access to a broader range of investment options.

otcqb financial

"common shares will continue to trade on the OTC Markets' OTCQB until the close"

OTCQB is a tier of the over‑the‑counter (OTC) market where smaller or developing companies list their shares for trading without being on a major stock exchange. Think of it like a well‑kept side street market: companies must meet basic reporting and transparency checks so investors get more information than the lowest OTC tier, but trading is usually less liquid and riskier than on big exchanges. Investors care because OTCQB listings can offer early access to growth stories but come with higher price swings and greater chance of limited resale options.

canadian securities exchange financial

"common shares will continue to trade on the Canadian Securities Exchange (CSE)"

A Canadian securities exchange is a regulated marketplace in Canada where companies’ stocks, bonds and other investment products are listed, bought, and sold. It matters to investors because it sets the rules, provides a visible price for securities and a place to trade — like a public marketplace that helps buyers and sellers meet, judge value, and convert holdings to cash under oversight intended to protect investors.

sedar+ regulatory

"details regarding the Offering will be provided through the Company's filings with the SEC and SEDAR+"

SEDAR+ is Canada’s centralized online system where publicly traded companies submit required regulatory documents such as financial reports, prospectuses and disclosure statements. It gives investors a single, searchable place — like a public library or online filing cabinet — to check a company’s official records for transparency, compare performance, and verify material information before making investment decisions.

securities and exchange commission regulatory

"details regarding the Offering will be provided through the Company's filings with the Securities and Exchange Commission"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

AI-generated analysis. Not financial advice.

HERZLIA, Israel and CALGARY, AB, Jan. 2, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that it anticipates to list on NYSE American on or around January 7, 2026, subject to approval of its listing application and continued compliance with exchange rules." subject to authorization of the application and continued compliance with the exchange rules.

 

In connection with the anticipated NYSE listing, Innocan is also conducting a concurrent offering of its securities, subject to market conditions and regulatory approval (the "Offering"). Additional details regarding the Offering will be provided through the Company's filings with the Securities and Exchange Commission ("SEC") and SEDAR+.

Innocan expects that its common shares will continue to trade on the OTC Markets' OTCQB until the close of the market on or about January 6, 2026. Upon effectiveness of the listing on the NYSE American, trading of the common shares on the OTCQB will terminate. Stockholders of Innocan do not need to take any action prior to the listing of Innocan's shares on the NYSE American. Innocan's common shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol "INNO".

This communication does not constitute an offer, or a solicitation of an offer, to buy or sell any securities, investment or other specific product, or a solicitation of any vote or approval, nor shall there be any sale of securities, investment or other specific product in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Innocan Pharma Corporation

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
www.innocanpharma.com 

For further information, please contact:

Iris Bincovich, CEO
15162104025+
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

Certain information set forth in this news release, including, without limitation, information regarding the anticipated listing on the NYSE American and the Offering, research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated listing and the Offering, benefits of Innocan'sproducts, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.

Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/innocan-pharma-corporation-anticipates-listing-on-the-nyse-american-stock-exchange-with-concurrent-offering-302651674.html

SOURCE Innocan Pharma Corporation

FAQ

When does Innocan expect to begin trading on NYSE American under ticker INNPD?

Innocan anticipates listing and beginning NYSE American trading on or around January 7, 2026, subject to approval.

Will Innocan shares stop trading on OTCQB when INNPD lists on NYSE American?

Yes; Innocan expects OTCQB trading to continue until the close of market on or about January 6, 2026, then terminate upon NYSE effectiveness.

Will Innocan remain listed in Canada after the NYSE American listing?

Yes; Innocan's common shares will continue to trade on the Canadian Securities Exchange under INNO.

Is Innocan conducting a securities offering alongside the NYSE listing?

Yes; the company is conducting a concurrent offering of securities, subject to market conditions and regulatory approval.

Do shareholders need to take action before Innocan lists on NYSE American?

No action is required from current stockholders prior to the anticipated NYSE American listing.